Yangtze River Pharmaceutical (Group) Co., Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website
stocktitan.net
·

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

Alvotech (NASDAQ: ALVO) announced its addition to the Nasdaq Biotechnology Index (NBI), effective December 23, 2024, reflecting its meeting of eligibility requirements including minimum market capitalization and average daily trading volume. The NBI comprises Nasdaq-listed companies classified as Biotechnology or Pharmaceuticals and is calculated using a modified capitalization-weighted methodology.
finance.yahoo.com
·

European Medicines Agency Confirms Acceptance of Marketing Authorization

EMA accepts Alvotech's MAA for AVT05, a biosimilar to Simponi® (golimumab), expected to complete approvals in Q4 2025.
biospace.com
·

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03

Alvotech announced EMA accepted a Marketing Authorization Application for AVT03, a biosimilar candidate to Prolia® and Xgeva® (denosumab). AVT03 met primary endpoints in studies demonstrating clinical similarity to Prolia in efficacy, safety, immunogenicity, and pharmacokinetics. Alvotech partners with STADA Arzneimittel AG and Dr. Reddy’s Laboratories SA for AVT03 commercialization in Europe.
globenewswire.com
·

European Medicines Agency Confirms Acceptance of Marketing

Alvotech announced EMA acceptance of its Marketing Authorization Application for AVT03, a biosimilar candidate to Prolia® and Xgeva® (denosumab). AVT03 aims to treat osteoporosis and prevent bone complications in cancer patients, potentially expanding patient access to affordable biologic medicines.
© Copyright 2024. All Rights Reserved by MedPath